Aptose Biosciences Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
  • Product Pipeline
    • Overview
    • Luxeptinib for B-cell Tumors
    • Luxeptinib for Myeloid Tumors
    • HM43239 for AML
    • Posters & Presentations
  • Clinical Trials
    • Overview
    • Luxeptinib for CLL & NHL
    • Luxeptinib for AML
    • HM43239 for AML
    • Expanded Access
  • News
    • Press Releases
    • Presentations
    • Events
  • Investors
    • Overview
    • News & Events
    • Company Info
    • Financial Info
    • Stock Data
    • SEC Filings
    • SEDAR
    • Governance
  • Careers
  • Contact

Presentations

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Presentations
    • Contacts
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Cash Flow
  • Stock Data
    • NASDAQ: APTO
    • TSX: APS
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • SEDAR
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Company Info

  • Overview
  • Management Team
  • Presentations
  • Contacts
Key Opinion Leader Symposium: CG-806 for AML

Key Opinion Leader Symposium: CG-806 for AML

Feb 5, 2020
2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

2019 ASH Poster - Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Dec 9, 2019
2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

2019 ASH Poster - CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Dec 8, 2019
Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253

Aptose Corporate Update at ASH 2019: Early Clinical Observations with CG-806 and APTO-253

Dec 7, 2019
2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML

2019 ESH Poster - CG-806 Pan-FLT3/Pan-BTK Inhibitor Simultaneously Suppresses Multiple Oncogenic Signaling Pathways to Treat AML

Oct 24, 2019
2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR

2019 EHA Poster - CG-806, PRECLINICAL IN VIVO EFFICACY AND SAFETY PROFILE AS A PAN-FLT3 / PAN-BTK INHIBITOR

Jun 14, 2019
24th Congress of The European Hematology Association 2019 - CG-806, Preclinica…

24th Congress of The European Hematology Association 2019 - CG-806, Preclinica…

May 16, 2019
2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells

2019 AACR Poster - Resistance to APTO-253 caused by internal deletion and alternate promoter usage of the MYC gene in Raji B cells

Apr 1, 2019
2019 AACR Poster - CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

2019 AACR Poster - CG-806, a pan-FLT3 / pan-BTK inhibitor, demonstrates superior potency against cells from IDH-1 mutant and other non-favorable risk groups of AML patients

Apr 1, 2019
Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers

Key Opinion Leader Breakfast: Novel Treatment for AML and B-cell Cancers

Dec 12, 2018
RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »
  • Email Alerts
  • Contacts
  • RSS News Feed
© 2022 Aptose Biosciences Inc. All Rights Reserved.
Privacy Policy Disclaimer Sitemap